MEGF11 Inhibitors
Chemical inhibitors of MEGF11 utilize various signaling pathways to achieve their inhibitory effects on the protein's function within cellular processes. Erlotinib, a known EGFR inhibitor, indirectly inhibits MEGF11 by suppressing the EGFR signaling pathway, which is intricately linked with cell proliferation and survival, thereby potentially reducing the activity of MEGF11 within these processes. Similarly, Dasatinib, which targets Src family kinases, may impede MEGF11 by blocking kinases that are involved in cell adhesion and migration, therefore possibly diminishing the functional involvement of MEGF11 in these pathways. LY294002 and Wortmannin, both PI3K inhibitors, can disrupt the PI3K/Akt pathway, crucial for cell survival and growth, thereby indirectly reducing MEGF11-mediated signaling. U0126 and PD98059, as MEK inhibitors, can interfere with the MEK/ERK pathway, implicated in cell cycle regulation and differentiation, and may thus decrease MEGF11 activity in these pathways.
Rapamycin, an mTOR inhibitor, may indirectly inhibit MEGF11 by disrupting mTOR signaling pathways involved in cell growth and proliferation. DAPT, as a gamma-secretase inhibitor, can prevent the cleavage of Notch receptors, thereby indirectly inhibiting MEGF11 in pathways that govern cell differentiation and proliferation. SB431542, which inhibits the TGF-beta type I receptor ALK5, can affect the TGF-beta signaling pathways and consequently reduce MEGF11's regulatory role in cell differentiation and migration. SP600125, a JNK inhibitor, can alter JNK signaling pathways involved in stress response and apoptosis, where MEGF11 could be active. Imatinib, targeting ABL, c-KIT, and PDGFR tyrosine kinases, can interfere with signaling pathways that regulate cell growth and survival, indirectly inhibiting MEGF11. Lastly, Sorafenib, a RAF inhibitor, can inhibit the RAF/MEK/ERK signaling cascade, which is involved in cell division and survival, and may thus influence MEGF11's involvement in these processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an EGFR inhibitor that could indirectly inhibit MEGF11 by suppressing the EGFR signaling pathway, which is associated with cell proliferation and survival processes within which MEGF11 may operate. Inhibition of EGFR can alter cellular signaling cascades, potentially diminishing MEGF11 activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib, a Src family kinase inhibitor, may indirectly inhibit MEGF11 by blocking Src family kinases that participate in multiple signaling pathways, including those related to cell adhesion and migration, where MEGF11 could be functionally involved. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor which could indirectly inhibit MEGF11 by downregulating the PI3K/Akt pathway, a key pathway for cell survival and growth, potentially decreasing MEGF11-mediated signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway, potentially resulting in decreased functional activity of MEGF11 due to its role in cell proliferation and differentiation pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which could lead to an indirect inhibition of MEGF11 by disrupting mTOR signaling pathways involved in cell growth and proliferation, processes where MEGF11 may play a role. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $99.00 $335.00 $836.00 $2099.00 | 47 | |
DAPT is a gamma-secretase inhibitor that could indirectly inhibit MEGF11 by preventing the cleavage and activation of Notch receptors, potentially reducing MEGF11 signaling in pathways involved in cell differentiation and proliferation. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 is an inhibitor of the TGF-beta type I receptor ALK5, which could indirectly inhibit MEGF11 by affecting TGF-beta signaling pathways that are implicated in cell differentiation and migration, processes potentially regulated by MEGF11. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is a JNK inhibitor, which may lead to indirect inhibition of MEGF11 by modulating JNK signaling pathways involved in stress response and apoptosis, where MEGF11 could be active. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an MEK inhibitor that could indirectly inhibit MEGF11 by disrupting the MEK/ERK pathway, which is linked to cell cycle regulation and differentiation, processes that may involve MEGF11. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor that could indirectly inhibit MEGF11 by interfering with the PI3K/Akt pathway, which is crucial for cell survival and metabolism, potentially impacting MEGF11 activity. | ||||||